Approval · Notice of Compliance 8718 · 2007
LIPITOR: Notice of Compliance 8718
Issued April 18, 2007
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 8718
- Date
- April 18, 2007
- Company
- Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication to reduce the risk of myocardial infarction in patients with clinically evident coronary heart disease and other revisions to the product monograph
- Therapeutic class
- Lipid metabolism regulator
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LIPITOR | Not yet assigned | — |
Medicinal ingredients
- ATORVASTATIN CALCIUM 10 MG per TAB
- ATORVASTATIN CALCIUM 20 MG per TAB
- ATORVASTATIN CALCIUM 40 MG per TAB
- ATORVASTATIN CALCIUM 80 MG per TAB